Skip to content

Definition, grading and diagnosis

TL;DR — Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system; symptoms alone do not prove it. The NeuPSIG system grades certainty as possible, probable or definite by combining a plausible lesion, neuroanatomically credible distribution, sensory signs and a confirmatory test (Finnerup 2016, PMID 27115670). Examination is the decisive bridge between history and testing, while questionnaires are screening aids rather than diagnostic instruments (Haanpää 2011, PMID 20851519; Truini 2023, PMID 37253688). Normal routine nerve-conduction studies do not exclude small-fiber disease, but abnormal QST alone also does not establish a lesion (Devigili 2020, PMID 32654574; Krumova 2012, PMID 22623149). The practical objective is an etiologic, anatomically coherent diagnosis with an explicit confidence grade—not merely the label “neuropathic.”

What the definition includes—and excludes

The 2008 redefinition replaced “dysfunction” with “lesion or disease,” narrowing the category to pathology affecting somatosensory pathways (Treede 2008, PMID 18003941). The 2016 revision retained that core but clarified how certainty should be assigned in clinical and research settings (Finnerup 2016, PMID 27115670).

Element Required interpretation Common error
Pain An unpleasant sensory and emotional experience Equating pain intensity with lesion severity
Lesion or disease Demonstrable or strongly supported pathology Calling unexplained burning a neuropathy
Somatosensory system Peripheral nerve, root, spinal cord, brainstem, thalamus or relevant cortex Including purely motor/autonomic lesions without somatosensory involvement
Neuroanatomical plausibility Distribution must fit the implicated structure Treating any leg pain with lumbar imaging as radicular neuropathic pain
Sensory evidence Negative and/or positive signs in the painful territory Counting descriptors without examination

Chronic neuropathic pain is represented as a distinct family in ICD-11, subdivided into peripheral and central forms and tied to an underlying neurologic lesion or disease (Scholz 2019, PMID 30586071). Nociceptive, nociplastic and neuropathic mechanisms can coexist; the grading system addresses the neuropathic component, not the total pain experience (Colloca 2017, PMID 28205574).

NeuPSIG grading algorithm

Grade Minimum evidence What it means What it does not mean
Possible Relevant lesion/disease history plus anatomically plausible pain distribution Neuropathic pain merits targeted examination/testing Treatment response confirms the diagnosis
Probable Possible criteria plus sensory signs in the same distribution Clinical evidence strongly supports neuropathic pain The etiology is proven
Definite Probable criteria plus objective confirmation of a relevant lesion/disease Highest diagnostic confidence Pain intensity or treatment responsiveness is predictable

The confirmatory test must explain the pain distribution. An incidental disc protrusion, nonspecific white-matter lesion or low intraepidermal nerve-fiber density outside the symptomatic pattern cannot by itself upgrade certainty (Finnerup 2016, PMID 27115670; Cohen 2014, PMID 24500412).

The grading system is not a severity scale. “Definite” describes causal confidence, not worse pain; “possible” may still be severe and function-limiting (Bouhassira 2019, PMID 30385075).

History: establish the candidate lesion

History should define onset, course, distribution, evoked versus spontaneous pain, sensory loss, weakness, autonomic change, exposure and disease context. Burning, electric shocks, painful cold, tingling, pins-and-needles and numbness increase suspicion but remain non-specific (Baron 2010, PMID 20650402).

Pattern Candidate localization High-yield etiologic context
Length-dependent feet before hands Distal polyneuropathy Diabetes, alcohol, renal disease, neurotoxic drugs
Single named-nerve territory Mononeuropathy Entrapment, trauma, surgery
Dermatomal or root territory Radiculopathy Disc disease, foraminal stenosis, tumor, infection
Unilateral trigeminal paroxysms Trigeminal pathway Neurovascular compression, multiple sclerosis, tumor
Below-level pain after cord lesion Central neuropathic pain Spinal cord injury or myelopathy
Hemibody pain after stroke Central neuropathic pain Spinothalamic/thalamocortical lesion
Patchy or non-length-dependent burning Small-fiber or ganglionopathy pattern Immune, metabolic, infectious, toxic, idiopathic

In spine-related leg pain, radicular pain, painful radiculopathy and somatic referred pain are often conflated. NeuPSIG recommends separate terminology and requires sensory signs plus appropriate evidence before assigning a neuropathic grade (Schmid 2023, PMID 37235637).

Examination: map signs, not adjectives

A standardized examination compares the painful area with a contralateral or adjacent control where possible. It should map light touch, pinprick, temperature, vibration, position sense, deep tendon reflexes and motor findings (Haanpää 2011, PMID 20851519).

Sign Bedside method Interpretation boundary
Hypoesthesia Cotton/light touch Large- or mixed-fiber loss; examiner-dependent
Hypoalgesia Pinprick Reduced nociceptive input; does not localize by itself
Thermal loss Warm/cool object Small-fiber clue; crude bedside precision
Allodynia Brush or light moving stimulus Gain of pain to normally nonpainful input
Hyperalgesia Repeated calibrated pinprick/pressure Increased pain to noxious input
Temporal summation Repeated equal stimuli Amplification clue; not disease-specific
Vibration loss 128-Hz tuning fork Large-fiber involvement
Weakness/areflexia Motor/reflex examination Helps localize nerve/root/large-fiber disease

Sensory loss is often more localizing than positive symptoms. A coherent deficit in the painful territory moves a case from possible to probable; isolated tenderness or widespread pressure sensitivity does not (Truini 2023, PMID 37253688).

Screening questionnaires

Tools such as DN4, painDETECT and LANSS can standardize symptom/sign capture, but their performance depends on setting and case mix. They estimate likelihood rather than proving a lesion, and should not replace neurologic examination (Haanpää 2011, PMID 20851519; Bouhassira 2019, PMID 30385075).

Appropriate use Inappropriate use
Epidemiologic case finding Declaring definite neuropathic pain
Trial prescreening Identifying etiology
Prompting a focused examination Selecting a drug mechanism
Monitoring descriptors over time Excluding neuropathy after a low score

Cancer guidance comparisons found inconsistent diagnostic recommendations among national documents, illustrating how case ascertainment can change prevalence and treatment estimates (Piano 2013, PMID 23279302). Contemporary cancer guidance still emphasizes lesion localization rather than symptom-score substitution (Mulvey 2024, PMID 39102168).

Development samples versus transportability

The landmark tools answer related but non-identical questions and were not validated against a single objective gold standard.

Instrument Development/validation evidence Quantitative result available from the report Transportability caution
LANSS Seven-item symptom-plus-examination scale; derivation n=60 and validation n=40 Discriminant ability and inter-rater agreement were assessed Small specialist samples; “neuropathic mechanisms dominate” is not a NeuPSIG certainty grade (Bennett 2001, PMID 11323136)
DN4 Ten symptoms/signs; prospective n=160, including 89 neurologic and 71 somatic lesions Expert independent diagnosis was the comparator Spectrum centered on traumatic nerve injury, PHN and post-stroke pain; accuracy may shift in primary care (Bouhassira 2005, PMID 15733628)
painDETECT Developed for chronic low-back pain; subsequently applied to about 8,000 people Paper version: sensitivity 85%, specificity 80%, positive predictive accuracy 83% Identifies a neuropathic component in back pain; does not establish root lesion or radiculopathy (Freynhagen 2006, PMID 17022849)
S-LANSS Community sample n=205 with clinical assessment Mail: sensitivity 57% (95% CI 46–69%), specificity 69% (61–77%); telephone: 52% (39–64%) and 78% (68–85%) Lower accuracy than initial validation; prevalence estimates are administration- and setting-sensitive (Weingarten 2007, PMID 17869424)

These data create a genuine guideline tension. Screening questionnaires improve consistency and case finding, but lesion-based frameworks resist using any score as confirmation. The most defensible workflow is screen → localize by examination → confirm the implicated lesion where feasible → state the certainty grade, retaining “possible” when testing is unavailable rather than silently upgrading the diagnosis.

Confirmatory testing by suspected lesion

Suspected lesion Test What a positive result establishes Important limitation
Large-fiber polyneuropathy Nerve-conduction studies/electromyography Physiologic large-fiber dysfunction and distribution Small fibers are not measured
Radiculopathy EMG plus MRI in context Root dysfunction and structural correlate Imaging abnormalities are common without symptoms
Small-fiber neuropathy Distal-leg skin biopsy Reduced age-adjusted intraepidermal nerve-fiber density Does not identify cause or prove that pain arises from loss
Small-fiber dysfunction Thermal QST/autonomic tests Functional sensory/autonomic abnormality Psychophysical or indirect; not independently diagnostic
Trigeminal neuralgia MRI protocol Secondary cause or neurovascular contact Contact alone is not always causal
Central post-stroke pain Brain MRI Lesion in relevant pathway Timing and somatotopy must fit
SCI pain Spinal MRI and neurologic level Cord lesion compatible with at-/below-level pain Lesion extent poorly predicts pain severity

Distal-leg skin biopsy with age-matched intraepidermal nerve-fiber norms carries a Level A recommendation for small-fiber neuropathy assessment, with laboratory quality control required (Lauria 2010, PMID 20642627). Yet a systematic review found that only 14% of idiopathic small-fiber neuropathy studies used the most common combined criteria, showing substantial definitional heterogeneity (Haroutounian 2021, PMID 32989823).

QST: useful phenotype, limited proof

The DFNS protocol measures 13 thermal and mechanical parameters in about 30 minutes and originally established reference data in 180 healthy participants; thresholds vary by body region, age and sex (Rolke 2006, PMID 16697110). Side-to-side comparison increased sensitivity by factors of 1.1–2.5 in the reference work (Rolke 2006, PMID 16697110).

QST captures both loss and gain but depends on attention, instructions and normative transformation. It cannot distinguish peripheral from central dysfunction along the tested pathway and cannot identify etiology (Backonja 2009, PMID 19692807; Krumova 2012, PMID 22623149).

For isolated small-fiber presentations, multiple tests may be complementary rather than hierarchical. An early clinical synthesis reported sensitivity ranges of 59–88% across epidermal nerve-fiber density, sudomotor, quantitative sensory and cardiovagal tests, while emphasizing that each captures a different structural or functional domain (Lacomis 2002, PMID 12210380). Those values are not interchangeable because reference standards and populations differed; concordance between a plausible phenotype and more than one abnormal domain is stronger evidence than maximizing any single test's sensitivity.

Etiology-specific grading nuances

Painful diabetic polyneuropathy

Diabetes plus foot pain is insufficient. A length-dependent sensory pattern and signs support probable neuropathic pain; nerve-conduction evidence can establish large-fiber disease, while skin biopsy or validated small-fiber tests may support isolated small-fiber involvement (Rosenberger 2020, PMID 32036431; Price 2022, PMID 34965987).

Trigeminal neuralgia

Diagnostic grading separates classical disease with neurovascular compression and morphological nerve-root change, secondary disease from an underlying disorder, and idiopathic disease without demonstrated cause (Cruccu 2016, PMID 27306631). MRI is recommended because clinical features cannot reliably exclude secondary trigeminal neuralgia (Bendtsen 2019, PMID 30860637).

Central neuropathic pain

AAPT criteria require a history of a central nervous-system lesion/disease, pain in a plausible body region, confirmatory neurologic signs and objective lesion evidence; competing nociceptive explanations must be assessed rather than assumed away (Widerström-Noga 2017, PMID 28666966).

Differential diagnosis and mixed pain

Mimic or co-mechanism Distinguishing question
Ischemic limb pain Are pulses, perfusion and exertional pattern abnormal?
Inflammatory arthropathy Is pain centered on inflamed joints with swelling/stiffness?
Myofascial pain Is distribution muscular and non-neuroanatomic?
Nociplastic amplification Is pain widespread without a focal somatosensory lesion?
Complex regional pain syndrome Are vasomotor, sudomotor, trophic and motor features present?
Medication toxicity Does timing follow chemotherapy, antimicrobials or excess vitamin exposure?
Functional neurologic symptoms Are positive inconsistency signs present?

Mixed mechanisms are expected in cancer, diabetes, spine disease and postsurgical pain. A neuropathic component should be graded independently rather than allowing one label to erase nociceptive or nociplastic contributors (Colloca 2017, PMID 28205574).

Diagnostic documentation minimum

  1. Name the suspected lesion or disease.
  2. Draw or describe the pain distribution.
  3. Record negative and positive sensory signs.
  4. State the confirmatory test and whether it explains the distribution.
  5. Assign possible, probable or definite confidence.
  6. Document important competing and coexisting mechanisms.
  7. Record functional impact and a baseline outcome measure.

“Pharmacoresistant” should not mean failure of one low-dose drug. A proposed definition requires adequate trials of recommended treatments with attention to dose, duration, adherence and outcome (Hansson 2009, PMID 19324579).

Open questions

  • Can a streamlined bedside examination preserve the accuracy of the full grading system in primary care? (Finnerup 2016, PMID 27115670; Truini 2023, PMID 37253688)
  • Which objective test combination should define isolated small-fiber neuropathy across laboratories? (Lauria 2010, PMID 20642627; Haroutounian 2021, PMID 32989823)
  • How often does imaging upgrade neuropathic certainty versus reveal incidental abnormalities in spine-related leg pain? (Schmid 2023, PMID 37235637)
  • Can QST add diagnostic value beyond a standardized bedside examination rather than merely increasing measurement density? (Krumova 2012, PMID 22623149)
  • Should central and peripheral mixed lesions receive dual grades in trials? (Widerström-Noga 2017, PMID 28666966)

References

  1. Finnerup NB, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157:1599-1606. PMID 27115670
  2. Treede RD, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70:1630-1635. PMID 18003941
  3. Haanpää M, et al. NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152:14-27. PMID 20851519
  4. Truini A, et al. Joint EAN-EFIC-NeuPSIG guidelines on neuropathic pain assessment. Eur J Neurol. 2023;30:2177-2196. PMID 37253688
  5. Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Rev Neurol (Paris). 2019;175:16-25. PMID 30385075
  6. Baron R, et al. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9:807-819. PMID 20650402
  7. Colloca L, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. PMID 28205574
  8. Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014;348:f7656. PMID 24500412
  9. Schmid AB, et al. Recommendations for terminology and identification of neuropathic pain in spine-related leg pain. Pain. 2023;164:1693-1704. PMID 37235637
  10. Rosenberger DC, et al. Challenges of neuropathic pain: focus on diabetic neuropathy. J Neural Transm. 2020;127:589-624. PMID 32036431
  11. Widerström-Noga E, et al. AAPT diagnostic criteria for central neuropathic pain. J Pain. 2017;18:1417-1426. PMID 28666966
  12. Cruccu G, et al. Trigeminal neuralgia: new classification and diagnostic grading. Neurology. 2016;87:220-228. PMID 27306631
  13. Bendtsen L, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol. 2019;26:831-849. PMID 30860637
  14. Piano V, et al. Diagnosing neuropathic pain in patients with cancer. Pain Pract. 2013;13:433-439. PMID 23279302
  15. Mulvey MR, et al. Neuropathic pain in cancer: what are the current guidelines? Curr Treat Options Oncol. 2024;25:1193-1202. PMID 39102168
  16. Devigili G, et al. Clinical diagnosis and management of small fiber neuropathy. Expert Rev Neurother. 2020;20:967-980. PMID 32654574
  17. Lauria G, et al. EFNS/PNS guideline on skin biopsy in small fiber neuropathy. Eur J Neurol. 2010;17:903-912. PMID 20642627
  18. Haroutounian S, et al. Diagnostic criteria for idiopathic small fiber neuropathy: systematic review. Muscle Nerve. 2021;63:170-177. PMID 32989823
  19. Rolke R, et al. DFNS quantitative sensory testing protocol and reference values. Pain. 2006;123:231-243. PMID 16697110
  20. Krumova EK, et al. Neuropathic pain: is quantitative sensory testing helpful? Curr Diab Rep. 2012;12:393-402. PMID 22623149
  21. Backonja MM, et al. QST in measurement of neuropathic pain phenomena. Clin J Pain. 2009;25:641-647. PMID 19692807
  22. Price R, et al. Oral and topical treatment of painful diabetic polyneuropathy: AAN guideline update. Neurology. 2022;98:31-43. PMID 34965987
  23. Strand N, et al. Small fiber neuropathy. Curr Pain Headache Rep. 2022;26:429-438. PMID 35384587
  24. Hansson PT, et al. Toward a definition of pharmacoresistant neuropathic pain. Eur J Pain. 2009;13:439-440. PMID 19324579
  25. Scholz J, et al. ICD-11 classification: chronic neuropathic pain. Pain. 2019;160:53-59. PMID 30586071
  26. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain. 2001;92:147-157. PMID 11323136
  27. Bouhassira D, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114:29-36. PMID 15733628
  28. Freynhagen R, et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22:1911-1920. PMID 17022849
  29. Weingarten TN, et al. Validation of the S-LANSS in the community setting. Pain. 2007;132:189-194. PMID 17869424
  30. Lacomis D. Small-fiber neuropathy. Muscle Nerve. 2002;26:173-188. PMID 12210380